FMC launches multiFiltratePRO: Fresenius Medical Care stock gains 1.17 percent

Published on 10/23/2026 at 09:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock costs EUR 39.64 on October 23, 2026, 1.17 percent above Xetra close. Q3 results are due November 3.

US rollout and earnings calendar

Fresenius Medical Care launched multiFiltratePRO in the United States on October 21, 2026.
Second-quarter revenue reached EUR 4.86 billion in 2026.
Fresenius Medical Care stock trades at EUR 39.64 at 9:40 a.m. CEST at Lang & Schwarz on October 23, 2026, 1.17 percent above the Xetra close of October 22, 2026.
DZ Bank cut its target to EUR 46.00 on October 21, 2026.
Third-quarter results are scheduled for November 3, 2026.

Schwarzweißfoto einer Pflegekraft, die ein Dialysegerät neben einem Patienten bedient — Schwarzweiß-Reportage zeigt Pflegekraft an Dialysegerät, symbolisch für Fresenius Medical Care AG DE0005785802 in klinischer Umgebung, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) was trading at EUR 39.64 at Lang & Schwarz on October 23, 2026 at 9:40 a.m. CEST, up 1.17 percent versus the Xetra close of October 22, 2026 at EUR 39.18. The company launched its multiFiltratePRO system in the United States on October 21, 2026, according to Fresenius Medical Care.

US launch adds treatment capacity

The launch gives U.S. hospitals access to a continuous kidney replacement therapy system with integrated citrate and calcium pumps. The company said the system received FDA clearance on October 19, 2026, and is intended for patients weighing at least 40 kilograms, according to the same October 21 release.

The product rollout adds a commercial milestone while the group prepares its next financial update. Fresenius Medical Care's second-quarter 2026 revenue was EUR 4.86 billion, up 1.40 percent from the second quarter of 2025, while operating profit was EUR 561.57 million, according to StockWatch. The same quarter produced net income attributable to common shareholders of EUR 218.38 million.

Three dated steps led here

On August 4, 2026, Fresenius Medical Care reported second-quarter revenue of EUR 4.86 billion. On October 19, 2026, research presented at ASN Kidney Week showed that 74.00 percent of more than 10,000 U.S. treatments reached the 23-liter high-volume hemodiafiltration target. On October 21, 2026, the company announced the multiFiltratePRO U.S. launch for patients with acute kidney injury.

What does the target imply?

DZ Bank cut its fair value estimate from EUR 54.00 to EUR 46.00 while retaining a Buy rating on October 21, 2026. The bank cited higher risks from proposed U.S. kidney-care reforms but also described FMC as well prepared in some areas, as reported by MarketScreener.

Next reporting dates

The investor calendar lists November 3, 2026 for the third-quarter financial results and November 6, 2026 for the quarterly financial report, according to Fresenius Medical Care. Those dates will give investors the first full financial read on the company after the new U.S. product launch.

Stock holds above the prior close

Fresenius Medical Care stock was trading at EUR 39.64 at Lang & Schwarz on October 23, 2026 at 9:40 a.m. CEST, 1.17 percent above the Xetra close of October 22, 2026 at EUR 39.18. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.